Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Efficacy of Xiidra in the Management Dry Eye Disease After Corneal Collagen Cross Linking

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05045053

Enrollment

Registered

2021-09-16

Start date

2021-02-01

Completion date

2022-01-31

Last updated

2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Disease

Keywords

dry eye, cross linking, xiidra

Brief summary

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Detailed description

first group of patients were treated with 0.5 % xiidra twice daily and artificial tears for 6 months.Second group treated with artificial tears for 6 months. the treatment starts after corneal collagen cross linking in both groups ,Baseline and post-treatment full ophthalmic examination was done.

Interventions

DRUGXiidra 5% Ophthalmic Solution

lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

computer based masking

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* corneal collagen cross linking

Exclusion criteria

* systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact lens wearers

Design outcomes

Primary

Measure	Time frame	Description
Change in Break up Time	6 months	fluorescein sodium stripes will be used for measurement of Break up Time in seconds at baseline and during the study

Countries

United Arab Emirates

Contacts

Primary ContactTarek R Elhamaky, M.D.

dr_thamakyy@yahoo.com+971 503207889

Backup ContactTarek Elhamaky